Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

BeyondSpring completes $3.2mm IPO

13 Mar 2017

Executive Summary

Cancer drug developer BeyondSpring Inc. completed its initial public offering on Nasdaq through the sale of 174.3k ordinary shares at $20. (The company originally filed to sell up to 476.2k shares at a range of $20-22.)
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By